Advances in the design and development of oncolytic measles viruses

Brian Hutzen1
Corey Raffel2
Adam W Studebaker1
1Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA; 2Department of Neurological Surgery and Pediatrics, University of California, San Francisco, San Francisco, CA, USA

Abstract: A successful oncolytic virus is one that selectively propagates and destroys cancerous tissue without causing excessive damage to the normal surrounding tissue. Oncolytic measles virus (MV) is one such virus that exhibits this characteristic and thus has rapidly emerged as a potentially useful anticancer modality. Derivatives of the Edmonston MV vaccine strain possess a remarkable safety record in humans. Promising results in preclinical animal models and evidence of biological activity in early phase trials contribute to the enthusiasm. Genetic modifications have enabled MV to evolve from a vaccine agent to a potential anticancer therapy. Specifically, alterations of the MV genome have led to improved tumor selectivity and delivery, therapeutic potency, and immune system modulation. In this article, we will review the advancements that have been made in the design and development of MV that have led to its use as a cancer therapy. In addition, we will discuss the evidence supporting its use, as well as the challenges associated with MV as a potential cancer therapeutic.

Keywords: virotherapy, measles virus, oncolytic therapy

Introduction
To minimize risk to the patient and general population, an ideal oncolytic virus should selectively kill tumor cells while being nonpathogenic to noncancerous tissue. The Edmonston strain of measles virus (MV-Edm) and its various derivatives meet these criteria. MV is a member of the genus Morbillivirus in the Paramyxoviridae family. MV is a spherical, enveloped virus that has a nonsegmented, single-stranded, negative-sense RNA genome that comprises approximately 16,000 nucleotides, encoding six genes that are translated into eight viral proteins.1,2

The vast majority of MV oncolytic therapy studies utilize derivatives of the MV-Edm strain. This strain was isolated in 1954 by John Enders and Thomas Peebles from a throat culture of a young boy named David Edmonston.3 Serial passaging of MV-Edm in human and monkey kidney cells resulted in the loss of the virus’s pathogenicity, allowing for the creation of the first live, attenuated MV vaccine in 1963.4 The safety of using MV-Edm clinically has been demonstrated over the last 50 years with over a billion human recipients worldwide.5 Furthermore, there has been no documentation of the reversion of MV-Edm back to pathogenic MV.

Three receptors that permit MV entry into human cells have been identified: signaling lymphocyte activation molecule, membrane cofactor protein (CD46), and nectin-4.6–8 CD46, a regulator of complement activation, is the preferred receptor for all laboratory strains of MV-Edm. This tropism was acquired following a single amino acid substitution at position 481, changing an asparagine to a tyrosine.9–11
Tumor selectivity is conferred by MV-Edm’s acquired tropism for CD46. Overexpression of CD46 is frequently seen in human cancer cells, where it most likely serves as a survival mechanism to protect the transformed cells from complement-mediated lysis. CD46 overexpression has been documented in numerous cancers including brain, breast, cervical, colorectal, endometrial, gastrointestinal, hepatocellular, lung, renal and ovarian carcinomas, and has also been reported in hematopoietic malignancies such as leukemia and multiple myeloma. Although CD46 is ubiquitously expressed on every nucleated cell in the human body, MV-Edm requires a minimum threshold of CD46 expression on the cell surface to initiate infection and fusion. The low CD46 densities associated with normal cells usually preclude MV-Edm infection and any subsequent intercellular fusion. Conversely, tumor cells express high levels of CD46, thus making them susceptible to MV-Edm infection, which leads to extensive intercellular fusion (syncytia) and subsequent cell death. The dependence on receptor density to generate a productive virus infection allows oncolytic viruses derived from MV-Edm to functionally discriminate between normal and transformed cells. In addition to its predilection for infecting tumor cells and its overall safety when administered clinically, the genome of MV-Edm is amenable to genetic manipulation. In 1996, Radecke et al developed a reverse genetic system for MV rescue that allowed recombinant MV to be generated from cDNA ushering in a new era of measles-based virotherapies. Genetic manipulation of MV cDNA has made it possible to build upon the already considerable strengths of MV-Edm mentioned above by creating novel MV with enhanced attributes and functions. In the last 20 years, investigations have centered around creating recombinant MV that produces detectable markers that monitor viral infection, express transgenes that confer enhanced oncolytic or immune-modulatory activity, and contain modifications that increase their selectivity for neoplastic tissue. In this article, we will review the advancements that have been made in the design and development of the original MV-Edm vaccine strain that have ultimately led to its use as a cancer therapy.

“Monitoring” oncolytic MVs
A critical component in evaluating oncolytic virus efficacy is the ability to monitor infection and spread. To facilitate its detection, recombinant MV-GFP and MV-CEA, two MV-Edm derivatives that encode green fluorescent protein (GFP) and carcinoembryonic antigen (CEA), respectively, were developed. Sequences coding for GFP and CEA were inserted into the 3′ end of MV genome before the N gene (Figure 1). Placement of the sequences here ensures maximal transcription and protein expression, thereby increasing the sensitivity of virus detection. MV-GFP is routinely used in in vitro evaluation when fluorescence microscopy techniques can be used to detect MV infection, whereas MV-CEA is used as a biomarker of in vivo infection when direct observation...

Figure 1. Summary of modifications introduced into MV-Edm through genetic engineering.
Notes: Location of the placement of the modifications within the genome is depicted. Functional contributions of the modifications are described as well. Descriptions of these recombinant viruses can be found in the text.
Abbreviations: MV-Edm, Edmonston strain of measles virus; GFP, green fluorescent protein; CEA, carcinoembryonic antigen; wt P, wild-type phosphoprotein; NIS, sodium iodide symporter; NAP, neutrophil-activating protein; PNP, purine nucleoside phosphorylase; GM-CSF, granulocyte macrophage colony-stimulating factor; a-PD-L1, anti-programmed death-1 ligand 1 antibody; a-CTLA-4, anti-cytotoxic T-lymphocyte antigen 4 antibody; ScFV, single chain fragment variable antibody.
Oncolytic measles therapy

is not possible.28,31 Following MV-CEA infection of tumor cells, CEA, a nonimmunogenic soluble peptide with no biological function, is released into the blood stream.29 As CEA has a constant circulation half-life, measurement of CEA levels in the patient’s serum can therefore provide useful information on the kinetics of MV infection. Important parameters including virus bioavailability, immune system involvement, and any potential dose-limiting toxicity can all be evaluated, making it possible to provide individualized medicine.30 The therapeutic potential of MV-CEA has already been demonstrated in multiple preclinical tumor models and is currently being tested in Phase I clinical trials for the treatment of recurrent ovarian cancer and glioblastoma multiforme (Table 1).32,33

To demonstrate tumor-specific infection in vivo, MV-NIS, a recombinant MV expressing the thyroidal sodium iodide symporter (NIS) gene, was constructed (Figure 1). NIS is a transmembrane ion channel that facilitates iodide transport into thyroid follicular cells.34,35 The administration of radioactive iodine and subsequent active uptake of iodide by cells can be used for imaging or ablation of the thyroid.36 Tumors infected with MV-NIS similarly acquire the ability to concentrate radioiodine, allowing anatomical mapping of the tumor and infectivity status to be monitored with single photon emission computed tomography or positron emission tomography imaging techniques using 131I and 124I, respectively, as tracers.34,37,38 Furthermore, MV-NIS therapy can also be combined with the β-emitting radioiodine isotope 123I to enhance the therapeutic potency of the virus (see “Arming”).14 The efficacy of MV-NIS treatment has been evaluated in preclinical models of multiple myeloma, ovarian cancer, pancreatic cancer, mesothelioma, prostate cancer, malignant gliomas, cancers of the head and neck, osteosarcoma, and medulloblastoma.34,39-46 Phase I/II clinical trials investigating MV-NIS in recurrent or refractory multiple myeloma, malignant pleural mesothelioma, ovarian epithelial cancer, and recurrent or metastatic squamous cell carcinoma of the head and neck are presently underway (Table 1).47-52

“Re-targeting” oncolytic MVs

Successful oncolytic viruses selectively kill cancer cells without causing excessive toxicity to non-neoplastic cells. To further assist in this outcome, recombinant MV has been engineered to target specific receptors overexpressed on tumor cells. As sequence determinants in the H gene are responsible for virus specificity, manipulation of the H gene to allow for targeted infection does not negatively impact subsequent virus fusion and syncytia formation mediated by the F protein.14 Mutations introduced in the H gene that ablates virus entry through the natural receptors CD46 and signaling lymphocyte activation molecule, combined with display of a tumor-specific ligand or single-chain antibody in the H gene, allow for the creation of retargeted MV (Figure 1).53-55 To ensure rescue of retargeted MV that no longer recognize their normal receptors, a pseudoreceptor STAR system was developed.56 This system utilizes Vero cells stably expressing a single-chain antibody against 6-His, which then allows the rescue of retargeted viruses that have been modified to express a 6-histidine tag at the N-terminus of the retargeted H protein.

Recombinant MV has successfully been developed to target multiple tumor-associated markers including the epidermal growth factor receptor, epidermal growth factor receptor-vIII, and interleukin-13 receptor α2 found on gliomas, myeloma markers CD38 and CD138, folate receptor α receptor expressed in ovarian cancers, prostate stem cell antigen expressed by prostatic and pancreatic cancers, CD20-positive non-Hodgkin’s lymphoma, and Her-2/neu.56-65 In each case, retargeted viruses retained their antitumor potency while restricting viral infection and replication to

Table 1 Summary of completed, ongoing, and actively recruiting clinical trials using measles virus

<table>
<thead>
<tr>
<th>Virus strain</th>
<th>Phase</th>
<th>Patient number</th>
<th>Cancer type</th>
<th>Route</th>
<th>Response and (reference)</th>
<th>Status</th>
<th>Trial identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>MV-CEA</td>
<td>I</td>
<td>46</td>
<td>Ovarian</td>
<td>IP</td>
<td>SD (32)</td>
<td>Completed</td>
<td>NCT00408590</td>
</tr>
<tr>
<td>MV-CEA</td>
<td>I</td>
<td>40</td>
<td>Glioblastoma multiforme</td>
<td>CNS</td>
<td>Recruiting</td>
<td>NCT00390299</td>
<td></td>
</tr>
<tr>
<td>MV-NIS</td>
<td>II/I</td>
<td>73</td>
<td>Multiple myeloma</td>
<td>IV</td>
<td>CR, PR (48)</td>
<td>Recruiting</td>
<td>NCT00450814</td>
</tr>
<tr>
<td>MV-NIS</td>
<td>II</td>
<td>12</td>
<td>Myeloma</td>
<td>IV</td>
<td>Recruiting</td>
<td>NCT02192775</td>
<td></td>
</tr>
<tr>
<td>MV-NIS</td>
<td>II/I</td>
<td>36</td>
<td>Multiple myeloma</td>
<td>IP</td>
<td>Recruiting</td>
<td>NCT0153177</td>
<td></td>
</tr>
<tr>
<td>MV-NIS</td>
<td>II/I</td>
<td>54</td>
<td>Ovarian</td>
<td>IPm</td>
<td>Recruiting</td>
<td>NCT02068794</td>
<td></td>
</tr>
<tr>
<td>MV-NIS</td>
<td>II</td>
<td>134</td>
<td>Ovarian, fallopian, peritoneal</td>
<td>IP</td>
<td>SD (105)</td>
<td>Recruiting</td>
<td>NCT02364713</td>
</tr>
<tr>
<td>MV-NIS</td>
<td>I</td>
<td>18</td>
<td>Head and neck</td>
<td>TTu</td>
<td>Recruiting</td>
<td>NCT01846091</td>
<td></td>
</tr>
</tbody>
</table>

Note: ClinicalTrials.gov identifier.

Abbreviations: MV-CEA, MV that expresses the carcinoembryonic antigen; MV-NIS, MV that expresses the sodium iodide symporter; IP, intraperitoneal; CNS, central nervous system; IV, intravenous; IP1, intrapleural; IPm, intraperitoneal using iNIS in recurrent or refractory multiple myeloma, medulloblastoma.

The efficacy of MV-NIS treatment has been evaluated in multiple preclinical tumor models and is currently being tested in Phase I clinical trials for the treatment of recurrent ovarian cancer and glioblastoma multiforme (Table 1).32,33

Furthermore, MV-NIS therapy can also be combined with the β-emitting radioiodine isotope 131I to enhance the therapeutic potency of the virus (see “Arming”).14 The efficacy of MV-NIS treatment has been evaluated in preclinical models of multiple myeloma, ovarian cancer, pancreatic cancer, mesothelioma, prostate cancer, malignant gliomas, cancers of the head and neck, osteosarcoma, and medulloblastoma.34,39-46 Phase I/II clinical trials investigating MV-NIS in recurrent or refractory multiple myeloma, malignant pleural mesothelioma, ovarian epithelial cancer, and recurrent or metastatic squamous cell carcinoma of the head and neck are presently underway (Table 1).47-52

“Re-targeting” oncolytic MVs

Successful oncolytic viruses selectively kill cancer cells without causing excessive toxicity to non-neoplastic cells. To further assist in this outcome, recombinant MV has been engineered to target specific receptors overexpressed on tumor cells. As sequence determinants in the H gene are responsible for virus specificity, manipulation of the H gene to allow for targeted infection does not negatively impact subsequent virus fusion and syncytia formation mediated by the F protein.14 Mutations introduced in the H gene that ablates virus entry through the natural receptors CD46 and signaling lymphocyte activation molecule, combined with display of a tumor-specific ligand or single-chain antibody in the H gene, allow for the creation of retargeted MV (Figure 1).53-55 To ensure rescue of retargeted MV that no longer recognize their normal receptors, a pseudoreceptor STAR system was developed.56 This system utilizes Vero cells stably expressing a single-chain antibody against 6-His, which then allows the rescue of retargeted viruses that have been modified to express a 6-histidine tag at the N-terminus of the retargeted H protein.

Recombinant MV has successfully been developed to target multiple tumor-associated markers including the epidermal growth factor receptor, epidermal growth factor receptor-vIII, and interleukin-13 receptor α2 found on gliomas, myeloma markers CD38 and CD138, folate receptor α receptor expressed in ovarian cancers, prostate stem cell antigen expressed by prostatic and pancreatic cancers, CD20-positive non-Hodgkin’s lymphoma, and Her-2/neu.56-65 In each case, retargeted viruses retained their antitumor potency while restricting viral infection and replication to
cells expressing the receptor. More importantly, retargeted strains, unlike their natural receptor-utilizing counterparts, displayed no off-target pathology following administration in a CD46 transgenic mouse model of MV toxicity.70

Although the ability to redirect MV tropism to generate more tumor-selective viruses is appealing, the utility of this approach remains clinically unproven. The impetus to reengineer MV tropism was based on the assumption that the ubiquitous expression of CD46 would result in MV infection and killing of normal cells.71 However, detailed studies determined that MV requires a minimum density of CD46 receptor density to induce cytopathic effect, and CD46 expression levels in normal cells are below this minimum threshold.72 Furthermore, no dose limiting toxicities have been reported in the Phase I clinical trials with the CD46-tropic MV-CEA and MV-NIS viruses that would warrant using an MV with altered tropism (Table 1).67 In the future, use of retargeted MV may be beneficial when the cellular CD46 expression level is insufficient to support virus-induced cytopathic effect.

An alternative approach to restrict viral tropism to tumor cells is the incorporation of microRNA target sites (miRTSs) into the viral genome.68,69 miRTS, which can inhibit translation, has been cloned into the 3′-untranslated region of both the viral fusion and hemagglutinin genes (Figure 1).68,69 Virus replication is controlled by differential microRNA expression documented in cancer cells. As numerous microRNAs are downregulated in cancer cells, virus replication is allowed to proceed, whereas the endogenous microRNA expression in normal cells prevents virus replication. Recombinant strains of MV have been engineered to contain target sites for brain-specific microRNA-7, liver-specific microRNA-122, and gastrointestinal-specific microRNA-148a.68,69 In vitro and in vivo studies demonstrated that normal cells and tissues restricted MV replication. In comparison, malignant cells and tissues were permissive for virus replication. In addition, miRTS specific for microRNA-7 protected mice susceptible to MV infection following an intracerebral challenge.68

“Arming” oncolytic MVs

Advances in genetic engineering have allowed investigators to create “armed” viruses that have increased antitumor efficacy. Armed viruses combine the lytic potential of the virus with the therapeutic capacity of a transgene cloned into the viral genome. The most widely studied therapeutic transgene utilized to arm recombinant MV is NIS. Apart from providing a noninvasive means of imaging tumors, MV-NIS (described in “Monitoring”) enhances the efficacy of MV against radiosensitive malignancies by concentrating radiodine in virus-infected cells.34 MV-NIS in combination with the β particle emitting radiodine isotope 131I significantly improved survival in preclinical models of multiple myeloma and prostate cancer.34,43 More recently, the combination of MV-NIS and 131I was found to have significant antitumor activity in orthotopic models of glioblastoma multiforme and medulloblastoma, radiosensitive brain tumors of adulthood and childhood, respectively.44,46

Investigators have also evaluated MV-PNP, an armed MV encoding the *Escherichia coli* purine nucleoside phosphorylase (PNP) gene (Figure 1).70 PNP is a prodrug convertase that catalyzes the prodrugs 6-methylpurine-2′-deoxyriboside (MeP-dR) and fludarabine (9-beta-D-arabinofuranosyl-2′-fluoro adenine 5′-monophosphate) into the highly cytotoxic 6-methylpurine and 2-fluoro adenine, respectively.71 These highly diffusible products are metabolized to toxic adenosine triphosphate analogs, which can subsequently arrest DNA, RNA, and protein synthesis.72 Co-administration of MV-PNP and MeP-dR significantly prolonged survival in a subcutaneous syngeneic model of murine colon adenocarcinoma.70 Complete tumor regression was also observed in nine out of ten animals when MV-PNP/MeP-dR was co-administered with the immunosuppressive agent cyclophosphamide.70 In separate studies, fludarabine increased the oncolytic efficacy of MV-PNP in xenograft models of Burkitt’s lymphoma and pancreatic cancer.62,64 Clinical trials with MV-PNP have yet to be formally proposed.

Another novel approach to increase the efficacy of MV-Edm is to replace the defective P gene associated with the vaccine strain with a wild-type P gene (Figure 1).72 During vaccine development, mutations in the MV-Edm P gene resulted in defects in the P, C, and V proteins transcribed from the P gene, thus rendering these proteins incapable of suppressing the type I interferon (IFN) response.57 As a result, tumor cells infected with MV-Edm produce substantially more IFNs than those infected with a wild-type MV, which can compromise viral gene expression.72 In a study by Haralambieva et al, the antitumor activity of a chimeric MV-GFP virus armed with the wild-type P gene was evaluated in vitro and in vivo.72 The chimeric virus induced significantly lower levels of type I IFN than unmodified MV-GFP and displayed greater oncolytic potency against human multiple myeloma xenografts. Despite the improved efficacy, clinical testing of this chimeric MV-Edm has not been pursued due to concerns in the potential pathogenicity associated with the wild-type P gene.14
“Immune-modulating” oncolytic MVs

Another strategy for improving the oncolytic potential of MV-Edm is to construct recombinant MV that expresses a transgene that stimulates the native antitumor immune response or alters the tumor microenvironment.74-76 MV-Edm derivatives have been constructed to express the immunostimulatory transgenes granulocyte macrophage colony-stimulating factor (GM-CSF) and IFN-β (Figure 1).42,77,78 GM-CSF potentiates many neutrophil functions including stimulation of phagocytosis, lysozyme release, oxidative metabolism, and recruitment of complement.79 IFN-β is involved in antibody production, natural killer and T-cell activation, and macrophage function.80,81 Treatment of a mouse xenograft model of Burkitt’s lymphoma with a recombinant MV expressing the murine GM-CSF (MV-mGM-CSF) induced infiltration of activated neutrophils and an antitumor response.78 MV strains expressing the murine IFN-β (MV-mIFN-B) induced CD68-positive immune cell infiltration, decreased CD31-positive vascular endothelial cells, and a significant antitumor response in xenograft models of human mesothelioma.42 MV-NAP, encoding a secreted form of the Helicobacter pylori neutrophil-activating protein (NAP), was also developed to modulate the immune system (Figure 1). NAP is a virulence factor involved in the pathogenesis of *H. pylori* infection and a potent modulator of proinflammatory cytokines.82 Treatment of xenograft models of lung and intra-pulmonary metastatic breast cancer with MV-NAP significantly prolonged survival.83 Increased survival was mediated in part by the induction of a nonspecific inflammatory reaction in the tumor microenvironment.83

MV derivatives were recently generated expressing antibodies against the immune checkpoint modulators cytotoxic T-lymphocyte antigen 4 (MV-aCTLA-4) and programmed death-1 ligand 1 (MV-aPD-L1) (Figure 1).84 CTLA-4 and PD-L1 are T-cell inhibitory factors that play critical roles in T-cell activation.85,86 Tumor cells co-opt these checkpoint modulators to escape cellular immunity, particularly against T-cells specific for tumor antigens. Results from clinical trials evaluating antibodies targeting CTLA-4 and PD-L1 have been encouraging, with antibodies blocking CTLA-4 being the first in the class of immune checkpoints to achieve US Food and Drug Administration approval. Recombinant MV expressing immune checkpoint modulators were constructed to restrict the toxicity associated with systemic antibody treatment to the tumor bed, as well as stimulate antitumor immunity. To evaluate the immunotherapeutic effects of oncolytic MV in vivo, a syngeneic model of malignant melanoma was established.84 MV-aCTLA-4 and MV-aPD-L1 treatment delayed tumor progression, while animals treated with MV-aPD-L1 had a significantly prolonged median overall survival. Both viruses were associated with a significant increase in CD3+ T-cells in the tumor and a decrease in FoxP3+ regulatory T-cells. Treatment with MV-aPD-L1 was associated with increased levels of CD8+ cytotoxic T-cells and activated IFN-γ-expressing CD8+ cells, as well as an increased CD8+ regulatory cell ratio. In vivo oncolytic efficacy of MV-aCTLA-4 and MV-aPD-L1 was evaluated in human melanoma xenografts.84 Tumor regression was observed in all treated mice, with complete remission achieved in 80% of the animals. Coupling the oncolytic potential of MV-Edm with immunotherapeutics may serve as novel treatment strategy.

“Immune-evading” oncolytic MVs

Due to previous vaccination or natural infection most candidates for measles virotherapy will have prior immunity to the virus, which may significantly impact the therapeutic efficacy.14,87,88 Circulating anti-MV antibodies and T-lymphocytes can rapidly neutralize an oncolytic MV. Furthermore, antibody titers progressively increase following each successive exposure, thus making re-administration of MV very difficult.89 Multiple approaches to circumvent or modulate anti-measles immunity are being evaluated. One possible strategy to modulate the immune response is to combine MV therapy with immunosuppressive agents such as cyclophosphamide.14 Previous studies with oncolytic strains of herpes virus demonstrated a decrease in the innate immune response, enhanced oncolytic activity, and prolonged viral gene expression in tumors following cyclophosphamide treatment.90-92 A preclinical toxicology study with MV-NIS performed in immunocompetent squirrel monkeys (Saimiri sciureus) reported similar findings.93 Cyclophosphamide treatment prior to intravenous administration of MV-NIS resulted in a decreased humoral immune response to the virus and a prolongation of viral gene expression.93 Importantly, no significant toxicity was reported in these animals.93 These preclinical observations have led to the inclusion of cyclophosphamide in a Phase I clinical trial evaluating MV-NIS in patients with recurrent or refractory multiple myeloma.47,48

A second novel strategy to circumvent the anti-measles immune response and improve viral delivery is to use infected cell carriers. In this approach, MV is delivered to the tumor in pre-infected cells such as monocytic cell lines or mesenchymal stem cells.94,95 Since no naked virions are present, antibodies cannot neutralize the virus. Ideally, cell carriers
are permissive to MV infection, display some capacity to traffic and deliver MV to tumor sites, and protect the virus from antibody neutralization.\textsuperscript{67} Cell carriers would also reduce sequestration of the virus by lung, liver, and spleen macrophages following systemic administration to treat disseminated and hematopoietic malignancies.\textsuperscript{96,97} In a preclinical study of ovarian cancer in passively immunized athymic mice, mesenchymal stem cells were shown to be susceptible to MV infection, migrate to the ovarian tumor xenograft, and provide a therapeutic benefit.\textsuperscript{95} Similar findings were reported in an orthotopic model of hepatocellular carcinoma in passively immunized SCID mice.\textsuperscript{98} These encouraging preclinical results have led to the creation of a Phase I clinical trial evaluating patient derived mesenchymal stem cells as carriers of MV-NIS in recurrent ovarian cancer (Table 1).\textsuperscript{30}

**Clinical considerations**

Before initiating clinical testing, the safety of MV-CEA and MV-NIS strains was extensively evaluated in mouse and primate models. Studies performed in a transgenic mouse lacking the IFN-α/β receptor and expressing the human CD46 receptor in a tissue-specific pattern similar to humans (Ifnar\textsuperscript{40} CD46 GE), demonstrated no toxicity following intraperitoneal, intravenous, or CNS delivery of the virus.\textsuperscript{66,99,100} Subsequent toxicology studies in measles-susceptible primates also demonstrated MV-NIS safety following CNS delivery in rhesus macaques (Macaca mulatta)\textsuperscript{101} and intravenous delivery in cynomolgus monkeys (Saimiri sciureus).\textsuperscript{95}

The safety and maximum tolerated dose of MV-CEA and MV-NIS are currently being evaluated in numerous Phase I clinical trials (Table 1).\textsuperscript{33,47-52} While data from many of these trials are still forthcoming, there have been no reports of dose-limiting toxicity following administration of intraperitoneal doses up to $10^9$ TCID$_{50}$, intravenous doses up to $10^{11}$ TCID$_{50}$, and CNS delivery of doses up to $10^7$ TCID$_{50}$. Results from the completed dose escalation trial involving intraperitoneal delivery of MV-CEA ($10^6$–$10^9$ TCID$_{50}$) demonstrated no dose-limiting toxicity or virus induced immunosuppression.\textsuperscript{32} Serum CEA levels, a marker of virus replication, were observed in patients receiving the highest dose ($10^9$ TCID$_{50}$). Significant decreases in cancer antigen-125 levels were observed in five patients, and median survival of patients in the trial (12.15 months) was double the historical expected median survival in this patient population (6 months).\textsuperscript{102} Based upon these results, a Phase I/II trial evaluating intraperitoneal administration of MV-NIS in treatment-resistant ovarian cancer was performed (Table 1).\textsuperscript{103} No dose-limiting toxicity was observed with MV-NIS doses up to $10^9$ TCID$_{50}$ $^{123}$I uptake was detected in the tumors of three patients indicating virus infection, and the overall median survival of 26.5 months compared favorably to studies evaluating novel therapeutics in this patient population (6–12 months).\textsuperscript{103} Interestingly, post-treatment evaluation showed an increase in IGFBP2 and Frα-specific effector T-cells, indicating a Th1 response against the ovarian cancer cells.\textsuperscript{103}

Finally, a recent report from a clinical trial investigating MV-NIS in recurrent drug-refractory multiple myeloma builds upon the encouraging results observed in ovarian cancer (Table 1).\textsuperscript{48} In the trial, two patients with multiple plasmacytomas responded to therapy following intravenous delivery of MV-NIS at a dose of $10^{11}$ TCID$_{50}$, with one patient experiencing durable complete remission at all disease sites.\textsuperscript{48} As MV-NIS infected cells express NIS and therefore concentrate iodine, single photon emission computed tomography was able to confirm tumor-specific infection following $^{123}$I administration. In the future, MV-NIS could be combined with high-energy beta-emitting $^{131}$I to increase the bystander effect surrounding infected cells. It should be noted that two factors may have contributed to the favorable response to therapy observed in these two patients. First, both patients had low pretreatment serum titers of anti-measles antibodies. Second, a very high dose of virus was administered. Previous experience in the ovarian cancer trials also suggested a dose-dependent response to therapy.\textsuperscript{32,103}

**Advantages and disadvantages of oncolytic MVs**

There is an ever-growing list of oncolytic viruses in preclinical and clinical testing. Although there are reviews describing the advantages and disadvantages associated with these viruses, there is virtually no information comparing their head-to-head efficacy. MVs offer numerous advantages when deciding to include oncolytic viruses as part of the therapeutic approach. As discussed in previous sections, the excellent safety profile associated with MV-Edm strains makes it an attractive candidate for oncolytic virotherapy compared with other oncolytic viruses not used as vaccine agents.\textsuperscript{5} In contrast to the oncolytic DNA genome containing adenoviruses (Ads) and herpes simplex viruses (HSV), MV with its RNA genome replicates in the cytoplasm of infected cells thus eliminating the possibility of insertional DNA mutagenesis. Similar to polioviruses and vaccinia viruses (VVs), MV has been genetically manipulated to select for preferential replication in cancer cells. In contrast, Ad, HSV,
and vesicular stomatitis viruses (VSVs) have been genetically engineered with mutations or deletions in genes required for replication in normal but not cancer cells. There are multiple mechanisms by which oncolytic viruses lead to the death of tumor cells. While many oncolytic viruses cause tumor death via direct cell lyses, including MV, Ad, and HSV, the ability of MV to form syncytia provides an additional mechanism of killing that many other oncolytic viruses do not possess. Expression of viral hemagglutinin and fusion proteins in MV infected cells interacts with CD46 expressed by noninfected neighboring cells thus creating a bystander effect. Recently multiple oncolytic viruses (MV, Ad, VV, and HSV) have been demonstrated to induce antitumor immunity. In this process, local infection induces inflammation leading to immune stimulation and recruitment of immune cells. Cellular debris generated by oncolysis is taken up by antigen-presenting cells. Tumor antigens can then trigger cellular or antibody-mediated immune responses.

While MV offer many advantages compared with other oncolytic viruses when deciding to conduct oncolytic virotherapy, there are disadvantages associated with MV. Although immunization has demonstrated the safety of MV-Edm administration and provides a safety barrier for subsequent exposure, serum neutralizing antibodies can potentially compromise oncolytic MV efficacy. This is extremely important when attempting to treat metastatic tumors where intravenous delivery of oncolytic viruses is necessary. In contrast, VV and VSV are two oncolytic viruses that have the potential to exhibit efficacy when delivered intravenously.

Conclusion and future directions

MV-Edm derivatives are a promising experimental approach to the treatment of cancer as they have demonstrated significant antitumor activity in multiple preclinical models. Furthermore, results from completed clinical trials demonstrate their safety and show early evidence of biologic activity in humans. Numerous genetic advancements have been made in the design and development of MV-Edm derivatives. These enhancements have attempted to increase their safety, potency, and ability to be monitored. Recombinant strains targeting tumor-specific markers, or containing microRNA recognition sites, were designed to restrict virus replication to tumor cells, therefore leaving normal cells unharmed. MV-Edm derivatives that express the E. coli PNP gene, contain the P gene from the wild-type virus, or express NIS have been constructed to increase virus CPE. Furthermore, CEA and NIS reporter genes have made real-time in vivo monitoring possible. There has been a recent impetus to construct MV-Edm derivatives that either evade the systemic immune response via infected cell carriers or illicit an antitumor immune response. Results regarding the safety and efficacy of MV therapy from ongoing clinical trials, coupled with continual evolution of MV-Edm derivatives, will help guide future development strategies, leading to a new generation of safer and more effective oncolytic MV.

Disclosure

The authors report no conflicts of interest in this work.

References


Oncolytic Virotherapy 2015:4 117


